MEI Pharma (MEIP) has provided an announcement.
MEI Pharma, Inc. has announced a strategic evaluation of its options, which may include potential transactions or an orderly company wind-down to maximize asset value. Concurrently, the firm is halting clinical development of its drug voruciclib, while still pursuing some non-clinical activities. Details are outlined in a presentation material provided in their recent report, which contains forward-looking statements subject to risks and uncertainties. The company has clarified that the presentation’s content is not considered a material disclosure nor is it filed under securities law.
For detailed information about MEIP stock, go to TipRanks’ Stock Analysis page.
